BioSig Technologies, Inc. (BSGM)
After hours:
| Previous close | 1.2800 |
| Open | 1.3000 |
| Bid | 1.2000 x 100 |
| Ask | 1.3400 x 100 |
| Day's range | 1.2500 - 1.3100 |
| 52-week range | 0.2620 - 16.5000 |
| Volume | |
| Avg. volume | 1,210,261 |
| Market cap | 13.998M |
| Beta (5Y monthly) | 0.70 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.9500 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 33.75 |
GlobeNewswireBioSig Technologies, Inc. Announces New Appointments to its Now Fully Constituted Board of Directors, which is Comprised of 5 Board Members, 3 Independent
Westport, CT, May 03, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) or (“BioSig” or "the Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced new appointments to its now fully constituted board of directors (the “Board”), which is comprised of a total of five (5) directors, three (3) of whom are classified as independent directors. The final compositions of the committees to the Board wi
- GlobeNewswire
BioSig Technologies, Inc. Appoints Mr. Anthony Amato to Position of Chief Executive Officer, Effective Immediately
Mr. Amato will also serve on the Company’s Board of DirectorsWestport, CT, April 30, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) or (“BioSig” or "the Company"), a medical technology Company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced the appointment of Mr. Anthony Amato to the Position of Chief Executive Officer (“CEO”), effective immediately. Additionally, Mr. Amato will serve on the Company’s Board of Directors, w
- GlobeNewswire
BioSig Engages Consulting Firm for Business Model Strategies
BAIPC will work to deploy a series of solutions to transform BioSig’s future courseWestport, CT, April 04, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company delivering unprecedented accuracy and precision to intracardiac signal visualization, announced today that it appointed Bridge Associates International Pharmaceutical Consulting (BAIPC) to advise on business model strategies. BAIPC will work to deploy a series of solut
